Salvianic borneol ester reduces β-amyloid oligomers and prevents cytotoxicity

References

• Behl C. (1997). Amyloid beta-protein toxicity and oxidative stress in Alzheimer’s disease. Cell Tissue Res, 290, 471–480.
   PubMed Web of Science ®Google Scholar
• Bi J, Jiang B, Liu JH, Lei C, Zhang XL, An LJ. (2008). Protective effects of catalpol against H2O2-induced oxidative stress in astrocytes primary cultures. Neurosci Lett, 442, 224–227.
   PubMed Web of Science ®Google Scholar
• Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. (2005). Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci, 8, 79–84.
   PubMed Web of Science ®Google Scholar
• Dahlgren KN, Manelli AM, Stine WB Jr, Baker LK, Krafft GA, LaDu MJ. (2002). Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem, 277, 32046–32053.
   PubMed Web of Science ®Google Scholar
• Fujiwara H, Iwasaki K, Furukawa K, Seki T, He M, Maruyama M, Tomita N, Kudo Y, Higuchi M, Saido TC, Maeda S, Takashima A, Hara M, Ohizumi Y, Arai H. (2006). Uncaria rhynchophylla, a Chinese medicinal herb, has potent antiaggregation effects on Alzheimer’s beta-amyloid proteins. J Neurosci Res, 84, 427–433.
   PubMed Web of Science ®Google Scholar
• Han M, Zhao CQ, Wang YY. (2009). β-(3,4-Dihydroxyphenyl)-α-hydroxypropanoates as amyloid peptide inhibitors and their preparation, pharmaceutical compositions and use in the treatment of neurodegenerative diseases. Faming Zhuanli Shenqing Gongkai Shuomingshu, Chinese patent, 21 pp. CN 101475483, A 20090708, CAN 151:220848, AN 2009: 840155.
   Google Scholar
• Hardy JA, Higgins GA. (1992). Alzheimer’s disease: The amyloid cascade hypothesis. Science, 256, 184–185.
   PubMed Web of Science ®Google Scholar
• Hawkes CA, Ng V, McLaurin J. (2009). Small molecule inhibitors of Aβ-aggregation and neurotoxicity. Drug Dev Res, 70, 111–124.
   Web of Science ®Google Scholar
• Hirohata M, Ono K, Yamada M. (2008). Non-steroidal anti-inflammatory drugs as anti-amyloidogenic compounds. Curr Pharm Des, 14, 3280–3294.
   PubMed Web of Science ®Google Scholar
• Jakob-Roetne R, Jacobsen H. (2009). Alzheimer’s disease: From pathology to therapeutic approaches. Angew Chem Int Ed Engl, 48, 3030–3059.
   PubMed Web of Science ®Google Scholar
• Jan A, Hartley DM, Lashuel HA. (2010). Preparation and characterization of toxic Abeta aggregates for structural and functional studies in Alzheimer’s disease research. Nat Protoc, 5, 1186–1209.
   Google Scholar
• Klunk WE, Jacob RF, Mason RP. (1999). Quantifying amyloid beta-peptide (Abeta) aggregation using the Congo red-Abeta (CR-abeta) spectrophotometric assay. Anal Biochem, 266, 66–76.
   PubMed Web of Science ®Google Scholar
• Lin HQ, Ho MT, Lau LS, Wong KK, Shaw PC, Wan DC. (2008). Anti-acetylcholinesterase activities of traditional Chinese medicine for treating Alzheimer’s disease. Chem Biol Interact, 175, 352–354.
   Google Scholar
• Lleó A, Greenberg SM, Growdon JH. (2006). Current pharmacotherapy for Alzheimer’s disease. Annu Rev Med, 57, 513–533.
   PubMed Web of Science ®Google Scholar
• Mecocci P, Mariani E, Polidori MC, Hensley K, Butterfield DA. (2008). Antioxidant agents in Alzheimer’s disease. Cent Nerv Syst Agents Med Chem, 8, 48–63.
   Google Scholar
• Mei Z, Zhang F, Tao L, Zheng W, Cao Y, Wang Z, Tang S, Le K, Chen S, Pi R, Liu P. (2009). Cryptotanshinone, a compound from Salvia miltiorrhiza modulates amyloid precursor protein metabolism and attenuates beta-amyloid deposition through upregulating alpha-secretase in vivo and in vitro. Neurosci Lett, 452, 90–95.
   PubMed Web of Science ®Google Scholar
• Porat Y, Abramowitz A, Gazit E. (2006). Inhibition of amyloid fibril formation by polyphenols: Structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des, 67, 27–37.
   PubMed Web of Science ®Google Scholar
• Reinke AA, Gestwicki JE. (2007). Structure-activity relationships of amyloid beta-aggregation inhibitors based on curcumin: influence of linker length and flexibility. Chem Biol Drug Des, 70, 206–215.
   PubMed Web of Science ®Google Scholar
• Ren Y, Houghton PJ, Hider RC, Howes MJ. (2004). Novel diterpenoid acetylcholinesterase inhibitors from Salvia miltiorhiza. Planta Med, 70, 201–204.
   PubMed Web of Science ®Google Scholar
• Shah RS, Lee HG, Xiongwei Z, Perry G, Smith MA, Castellani RJ. (2008). Current approaches in the treatment of Alzheimer’s disease. Biomed Pharmacother, 62, 199–207.
   PubMed Web of Science ®Google Scholar
• Tabner BJ, Turnbull S, El-Agnaf OM, Allsop D. (2002). Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer’s disease and Parkinson’s disease. Free Radic Biol Med, 32, 1076–1083.
   PubMed Web of Science ®Google Scholar
• Yankner BA, Duffy LK, Kirschner DA. (1990). Neurotrophic and neurotoxic effects of amyloid beta protein: Reversal by tachykinin neuropeptides. Science, 250, 279–282.
   PubMed Web of Science ®Google Scholar
• Yu XY, Lin SG, Chen X, Zhou ZW, Liang J, Duan W, Chowbay B, Wen JY, Chan E, Cao J, Li CG, Zhou SF. (2007). Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer’s disease, across the blood–brain barrier. Curr Drug Metab, 8, 365–378.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yu H, Sun Y, Lin X, Chen B, Tan C, Cao G, Wang Z. (2007). Protective effects of salidroside on hydrogen peroxide-induced apoptosis in SH-SY5Y human neuroblastoma cells. Eur J Pharmacol, 564, 18–25.
   PubMed Web of Science ®Google Scholar
• Zhao B. (2009). Natural antioxidants protect neurons in Alzheimer’s disease and Parkinson’s disease. Neurochem Res, 34, 630–638.
   PubMed Web of Science ®Google Scholar
• Zheng XH, Zhang QS, Wang SX, Zhao XF. (2007). Preparation of β-phenyl-α-hydroxypropionic acid derivatives for treatment of cardiovascular and cerebrovascular diseases. PCT Int Appl, 46 pp. WO 2007131446, A1 20071122, CAN 150:514768, AN 2009:647929.
   Google Scholar
• Zhou L, Zuo Z, Chow MS. (2005). Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol, 45, 1345–1359.
   PubMed Web of Science ®Google Scholar
• Zhu X, Su B, Wang X, Smith MA, Perry G. (2007). Causes of oxidative stress in Alzheimer disease. Cell Mol Life Sci, 64, 2202–2210.
   PubMed Web of Science ®Google Scholar